The iShares Biotech exchange-traded fund reached a significant milestone by testing its all-time high, cementing a 27% gain year-to-date. This performance aligns the biotech sector with the broader technology market, which has dominated investor sentiment for much of the current fiscal cycle. Market participants are increasingly viewing biotech volatility as a primary driver for broader health care indices, moving away from defensive positioning toward high-growth thematic assets.